ImmunityBio/$IBRX
1D1W1MYTD1Y5YMAX
Capital at risk
About ImmunityBio
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
- Ticker
- $IBRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 688
- Headquarters
- San Diego, United States
- Website
- immunitybio.com
ImmunityBio Metrics
BasicAdvanced
$11B
-
-$0.99
0.13
-
Price and volume
Market cap
$11B
Beta
0.13
52-week high
$12.43
52-week low
$1.95
Average daily volume
11M
Financial strength
Current ratio
5.721
Quick ratio
5.355
Long term debt to equity
-1.167
Total debt to equity
-1.175
Interest coverage (TTM)
-2.20%
Profitability
EBITDA (TTM)
-235.298
Gross margin (TTM)
99.34%
Net profit margin (TTM)
-598.56%
Operating margin (TTM)
-151.88%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-30.54%
Return on equity (TTM)
122.86%
Valuation
Price to revenue (TTM)
62.268
Price to book
-10.35
Price to tangible book (TTM)
-10.23
Price to free cash flow (TTM)
-35.782
Free cash flow yield (TTM)
-2.79%
Free cash flow per share (TTM)
-0.287
Growth
Revenue change (TTM)
192.92%
Earnings per share change (TTM)
104.25%
3-year revenue growth (CAGR)
554.26%
3-year earnings per share growth (CAGR)
-4.55%
What the Analysts think about ImmunityBio
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
Analyst projections of the future price of ImmunityBio stock.
Bulls say / Bears say
ANKTIVA sales are scaling: second-quarter 2026 product revenue rose 92% year on year to $50.7 million and 15% sequentially, extending the run of quarterly growth. The company also reported $357.4 million in cash and marketable securities at quarter end. (ImmunityBio)
The UAE authorised ANKTIVA for both bladder cancer and metastatic lung cancer, taking its footprint to five regulatory jurisdictions and 34 countries. This creates scope for further international sales, although commercial uptake remains to be proven. (ImmunityBio)
ImmunityBio said its pivotal trial of ANKTIVA plus BCG in BCG-naïve bladder cancer was fully enrolled, with the independent monitoring committee confirming no extra enrolment was needed. The company planned a supplemental FDA application in 2026, offering a potential route to broaden use beyond the current market. (ImmunityBio)
Cash burn remains substantial: ImmunityBio used $141.9 million in operating cash in the first half of 2026, and its filing says it may need further funding to support operations. Reliance on new equity or affiliated financing could dilute shareholders or increase financial dependence. (StockTitan)
FDA concerns over ANKTIVA promotional communications forced the company to remove material and review its claims and compliance processes. Further regulatory scrutiny could distract management and complicate efforts to build prescriber confidence. (BioSpace)
Approval of ANKTIVA for papillary-only bladder cancer is not assured: the FDA said its review will focus on whether the evidence justifies applying results from patients with carcinoma in situ to this group, and reiterated concerns about the single-arm data. A negative decision could limit this potential expansion of the market. (ImmunityBio)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2026.
ImmunityBio Financial Performance
Revenues and expenses
ImmunityBio Earnings Performance
Company profitability
Upcoming events
No upcoming events
ImmunityBio News
AllArticlesVideos
ImmunityBio Stock Jumps: What's Going On?
Benzinga2 days ago
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
Business Wire2 months ago
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
Business Wire2 months ago
Funds containing ImmunityBio
AllUSDGBPEUR
Fund name | Fund size | $IBRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.66% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.66% |
iShares Healthcare Innovation$HEAL | $1.4B | 0.34% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.34% |
iShares Healthcare Innovation£DRDR | £1B | 0.34% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.